STAR*D ‘Diligent Delivery of Care’ Model Yields Remission Gains
STAR*D ‘Diligent Delivery of Care’ Model Yields Remission Gains
Half of patients with nonpsychotic major depressive disorder can achieve symptomatic remission with no more than 2 treatments, provided those treatments are diligently delivered with careful adjustments of medication doses, according to A. John Rush, MD, principal investigator of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
Speaking at a recent press teleconference organized by the National Institute of Mental Health (NIMH),1 Rush called the results good news, considering that the outpatients who participated in the study, ranging in age from 18 to 75 years, were real world patients.
A 50% remission rate is extraordinarily good, given the nature of these disorders, said Rush, who is vice chairman of clinical sciences and professor of psychiatry at the University of Texas Southwestern Medical Center, Dallas. These individuals have had about 16 years of illness and have had an average of more than 2 years in a current episode; two thirds have other psychiatric conditions, such as generalized anxiety disorder, panic disorder, or post-traumatic stress disorder; and about two thirds have concomitant current general medical problems. All of these additional illness burdens reduce the probability of achieving remission and may prolong the time to get to remission.
NIMH funded the 6-year, $35- million effectiveness STAR*D trial to help address the public health challenge of depression, said NIMH director Thomas Insel, MD. Government and research statistics indicate that depression affects 6.7% of the adult US population, begins early in life, is the leading cause of disability in Americans aged between 15 and 44 years, is a major factor in suicides, and costs the nation an estimated $83.1 billion annually (year 2000 estimates), which includes $26.1 billion in direct treatment costs and $57 billion in reduced productivity, absenteeism, and lost earnings as a result of suicide.2
Even though antidepressants are one of the most commonly prescribed medications in the United States, depression has not gone away, Insel noted. Why is this the case?
The easy answer is that roughly half the people with depression do not get treatment, and of those who do get treatment, only about 40% receive an evidence-based treatment, such as [an] adequate dose of an SSRI [selective serotonin reuptake inhibitor] for an adequate period of time, he said. The more difficult answer to that question is that even those who get optimal treatment may not get well. We know that in a 12-week trial with an adequate dose of an antidepressant, about half get better and one third get well; that leaves two thirds still needing another treatment.
Insel was alluding to the Level 1 results of the STAR*D trial.3 At Level 1, participants took the SSRI citalopram (Celexa), and the response rates were comparable across 23 psychiatric and 18 primary care treatment sites. Out of an analyzable sample of 2876 outpatients, about one third of the participants reached remission (28% per the 17-item Hamilton Depression Rating Scale [HAM-D] and 33% per the Quick Inventory of Depressive Symptomatology, Self-Report [QIDSSR]). 3 If they chose to stay in the study, they continued on citalopram and entered a citalopram follow-up phase.
For remission, the mean dose of citalopram (41.8 mg/d) was higher and the mean duration of treatment (47 days with 5.5 visits) was longer than might have been expected on the basis of current clinical practice.4 In Level 1, 20% of the patients (592) exited the study.
Patients who did not achieve remission or who could not tolerate citalopram were invited to participate in Level 2 of the trial, which offered 7 different treatments options for up to 14 weeks. Four options switched the study participants to sustained-release bupropion (Wellbutrin SR; maximum dosage, 400 mg/d), sertraline (Zoloft; maximum dosage, 200 mg/d), extended-release venlafaxine (Effexor XR; maximum dosage, 375 mg/d), or cognitive therapy (CT). Three options augmented citalopram by adding either sustainedrelease bupropion (mean ending dosage, 267.5 mg/d), buspirone (BuSpar; mean ending dosage, 40.9 mg/d), or CT. The results for the medication trials are reported in 2 articles recently published in the New England Journal of Medicine.5,6 The CT results, as both a switch and add-on alternative, are expected to be published in the fall.
A total of 1439 patients entered Level 2. About 1 in 4 of the 727 people who participated in the switch study became symptom-free, which was about the same in each of the 3 medication groups.
No one medication was clearly better than another, even though these treatments . . . have different pharmacologic effects. So, which treatment is used may be less important than that the drugs be used diligently and appropriately with proper dose adjustments and the measurement of symptoms and side effects, said Rush. Patients and doctors should note that they should not give up treatment after 4 weeks, which is currently common practice, because the study showed that about one third of those who ultimately did benefit either in terms of response or remission did so after 4 and even after 6 weeks. Our trial suggests that longer treatment with current medications would be beneficial.
In the journal article on the switch portion of the study, Rush and colleagues noted that contrary to the belief that intolerance of one SSRI predicts intolerance of another SSRI, sertraline was tolerated as well as sustained-release bupropion, even though 56% of the patients in this trial could not tolerate citalopram. Thus, intolerance to or the lack of efficacy of one SSRI seems not to imply intolerance or lack of efficacy of another SSRI. These results indicate that both withinclass and out-of-class medication switches are reasonable choices.5
About 1 in 3 of the 565 participants in the augmentation study achieved remission when a second medication was added to citalopram. The sustainedrelease bupropion group and the buspirone group had similar rates of remission, as assessed using the 17-item HAM-D and the 16-item QIDS-SR, but bupropion was associated with a greater reduction (from baseline to the end of the study) in QIDS-SR scores than was buspirone. Compared with buspirone, bupropion was also associated with fewer side effects and adverse effects.6
Study participants who still did not achieve remission in Level 2 had the option of completing up to 2 additional levels of treatment. Options at Level 3 were mirtazapine (Remeron) or nortriptyline (Aventyl, Pamelor) as monotherapies or augmentation with lithium (Eskalith, Lithobid) or a thyroid hormone (T3). Participants in Level 4 could switch to tranylcypromine (Parnate) or to a combination of extended- release venlafaxine and mirtazapine. Results from Levels 3 and 4 of the STAR*D trial will be published later this year.